Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
暂无分享,去创建一个
D. Centonze | M. Rovaris | C. Pozzilli | G. Comi | G. Comi | M. Trojano | A. Ghezzi | R. Bergamaschi | C. Gasperini | R. B. Bossio | M. Mirabella | P. Cavalla | M. Zappia | F. Patti | M. Amato | E. Sessa | S. Bonavita | P. Valentino | A. Iudice | A. Francia | C. Solaro | V. Brescia Morra | E. Montanari | M. Marrosu | S. Messina | D. Spitaleri | G. Lus | G. Maniscalco | S. Cottone | A. Gajofatto | M. Marrosu | G. Costantino | V. Morra | M. Matta | M. Danni | R. Bruno Bossio
[1] L. Leocani,et al. Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study , 2016, Neurological Sciences.
[2] E. Houdayer,et al. Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis , 2015, Journal of Neurology.
[3] C. Oreja-Guevara,et al. Observational Safety Study of THC:CBD Oromucosal Spray (Sativex) in Multiple Sclerosis Patients with Spasticity , 2015 .
[4] S. Meuth,et al. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis , 2015, Expert review of neurotherapeutics.
[5] Ó. Fernández. Advances in the Management of MS Spasticity: Recent Observational Studies , 2014, European Neurology.
[6] U. Zettl,et al. Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice , 2014, European Neurology.
[7] U. Zettl,et al. Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity , 2014, European Neurology.
[8] W. Feneberg,et al. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity , 2014, The International journal of neuroscience.
[9] Carlo Pozzilli,et al. Overview of MS Spasticity , 2014, European Neurology.
[10] C. Pozzilli,et al. A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis , 2011, European journal of neurology.
[11] C. Vila,et al. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the ‘5E’ study , 2011, Expert review of pharmacoeconomics & outcomes research.
[12] C. Collin,et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis , 2010, Neurological research.
[13] J. Farrar,et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. , 2008, Clinical therapeutics.
[14] C. Collin,et al. Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis , 2007, European Journal of Neurology.
[15] D. Wade,et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis , 2006, Multiple sclerosis.
[16] Jordi Perez. Combined cannabinoid therapy via an oromucosal spray. , 2006, Drugs of today.
[17] T. Vollmer,et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients , 2004, Multiple sclerosis.
[18] D. Wade,et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients , 2004, Multiple sclerosis.
[19] C. Young,et al. Anti-spasticity agents for multiple sclerosis. , 2003, The Cochrane database of systematic reviews.
[20] S. Haque. Ethics approval This study was conducted with the approval of the East London and City Health Authority Ethic Committee. Provenance and peer review Not commissioned; externally peer reviewed. , 2011 .
[21] J. Wight,et al. Treatments for spasticity and pain in multiple sclerosis: a systematic review. , 2003, Health technology assessment.